UB Paderborn / Katalog / Suche / in CDI

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3892-3901

2007

Link zum Volltext

Verfügbarkeit prüfen

Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4522-4529

2009

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

The New England journal of medicine, 2021-07, Vol.385 (1), p.46-58

2021

Link zum Volltext

Verfügbarkeit prüfen

Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone

Clinical cancer research, 2007-12, Vol.13 (24), p.7480-7486

2007

Link zum Volltext

Verfügbarkeit prüfen

Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy

The cancer journal (Sudbury, Mass.), 2009-09, Vol.15 (5), p.395

2009

Link zum Volltext

Verfügbarkeit prüfen

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

Cancer, 2008-04, Vol.112 (7), p.1529-1537

2008

Link zum Volltext

Verfügbarkeit prüfen

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

Annals of hematology, 2010-11, Vol.89 (11), p.1133-1140

2010

Link zum Volltext

Verfügbarkeit prüfen

A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days

Cancer, 2005-05, Vol.103 (9), p.1932-1938

2005

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome

Clinical lymphoma, myeloma and leukemia, 2011-02, Vol.11 (1), p.44-49

2011

Link zum Volltext

Verfügbarkeit prüfen

Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment

Clinical lymphoma & myeloma, 2008-12, Vol.8 (6), p.352-355

2008

Link zum Volltext

Verfügbarkeit prüfen

Prostate cancer metastatic to skin

Urology (Ridgewood, N.J.), 2003-02, Vol.61 (2), p.456-457

2003

Link zum Volltext

Verfügbarkeit prüfen

Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer

Journal of clinical oncology, 2002-10, Vol.20 (19), p.4124-4126

2002

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5152: Estimating the fraction of a tumor that is killed by a drug

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.5152-5152

2013

Link zum Volltext

Verfügbarkeit prüfen

Oophorectomy in Carriers of BRCA Mutations

The New England journal of medicine, 2002-09, Vol.347 (13), p.1037-1040

2002

Link zum Volltext

Verfügbarkeit prüfen

Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin

Blood, 2009-11, Vol.114 (22), p.109-109

2009

Link zum Volltext

Verfügbarkeit prüfen

The Combination of Pegylated Liposomal Doxorubicin and Bortezomib Significantly Improves Time to Progression of Patients with Relapsed/Refractory Multiple Myeloma Compared with Bortezomib Alone: Results from a Planned Interim Analysis of a Randomized Phase III Study

Blood, 2006-11, Vol.108 (11), p.404-404

2006

Link zum Volltext

Verfügbarkeit prüfen

The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure

Blood, 2007-11, Vol.110 (11), p.410-410

2007

Link zum Volltext

Verfügbarkeit prüfen

Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma

Blood, 2007-11, Vol.110 (11), p.2740-2740

2007

Link zum Volltext

Verfügbarkeit prüfen

Preparation of Artificial Antigen and Egg Yolk-derived Immunoglobulin （IgY） of Citrinin for Enzyme-Linked Immunosorbent Assay

Biomedical and environmental sciences, 2009 (3), p.237-243

ZHAO-HUI DUAN ZHUANG-SEN LIN HE-RUI YAO YAN-HONG GAO KUN ZHANG Su-QING ZHAO ZHEN-YU ZHU

2009

Link zum Volltext

Verfügbarkeit prüfen

Detection of Antibody to Hepatitis Delta Virus in Human Serum by Double Antigen Sandwich ELISA

Virologica Sinica, 2009-02, Vol.24 (1), p.45-51

2009

Link zum Volltext

Verfügbarkeit prüfen

Deep sequencing of the MHC region in the Chinese population contributes to studies of complex disease

Nature genetics, 2016-07, Vol.48 (7), p.740-746

2016

Link zum Volltext

Verfügbarkeit prüfen

3',4',5',5,7-Pentamethoxyflavone Sensitizes Cisplatin-Resistant A549 Cells to Cisplatin by Inhibition of Nrf2 Pathway

Molecules and Cells, 2015, 38(5), , pp.396-401

2015

Link zum Volltext

Verfügbarkeit prüfen

"Yellow-dragon Wonderful-seed Formula" for hyperuricemia in gout patients with dampness-heat pouring downward pattern: a pilot randomized controlled trial

Trials, 2018-10, Vol.19 (1), p.551-10, Article 551

2018

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone

Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days

Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome

Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment

Prostate cancer metastatic to skin

Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer

Abstract 5152: Estimating the fraction of a tumor that is killed by a drug

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

Oophorectomy in Carriers of BRCA Mutations

Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin

The Combination of Pegylated Liposomal Doxorubicin and Bortezomib Significantly Improves Time to Progression of Patients with Relapsed/Refractory Multiple Myeloma Compared with Bortezomib Alone: Results from a Planned Interim Analysis of a Randomized Phase III Study

The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure

Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma

Preparation of Artificial Antigen and Egg Yolk-derived Immunoglobulin （IgY） of Citrinin for Enzyme-Linked Immunosorbent Assay

Detection of Antibody to Hepatitis Delta Virus in Human Serum by Double Antigen Sandwich ELISA

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Deep sequencing of the MHC region in the Chinese population contributes to studies of complex disease

3',4',5',5,7-Pentamethoxyflavone Sensitizes Cisplatin-Resistant A549 Cells to Cisplatin by Inhibition of Nrf2 Pathway

"Yellow-dragon Wonderful-seed Formula" for hyperuricemia in gout patients with dampness-heat pouring downward pattern: a pilot randomized controlled trial

Suchergebnisse filtern